News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
666,670 Results
Type
Article (62416)
Company Profile (77)
Press Release (604168)
Multimedia
Podcasts (102)
Webinars (21)
Section
Business (174201)
Career Advice (2749)
Deals (32545)
Drug Delivery (116)
Drug Development (77160)
Employer Resources (154)
FDA (15175)
Job Trends (13949)
News (306105)
Policy (29194)
Tag
2027 Biotech Bay Standard (1)
2027 Pharm Country Standard (2)
Academia (2909)
Academic (2)
Accelerated approval (33)
Adcomms (28)
Allergies (142)
Alliances (43294)
ALS (167)
Alzheimer's disease (1599)
Antibody-drug conjugate (ADC) (290)
Approvals (15449)
Artificial intelligence (528)
Autoimmune disease (160)
Automation (37)
Bankruptcy (291)
Best Places to Work (10854)
BIOSECURE Act (16)
Biosimilars (176)
Biotechnology (55)
Bladder cancer (154)
Brain cancer (60)
Breast cancer (625)
Cancer (4695)
Cardiovascular disease (392)
Career advice (2347)
Career pathing (40)
CAR-T (288)
CDC (45)
Celiac Disease (2)
Cell therapy (764)
Cervical cancer (35)
Clinical research (66070)
Collaboration (1649)
Company closure (5)
Compensation (713)
Complete response letters (56)
COVID-19 (2684)
CRISPR (92)
C-suite (900)
Cystic fibrosis (144)
Data (6107)
Decentralized trials (2)
Denatured (41)
Depression (132)
Diabetes (470)
Diagnostics (6469)
Digital health (45)
Diversity (13)
Diversity, equity & inclusion (40)
Drug discovery (245)
Drug pricing (185)
Drug shortages (25)
Duchenne muscular dystrophy (212)
Earnings (63365)
Editorial (59)
Employer branding (18)
Employer resources (138)
Events (98685)
Executive appointments (1032)
FDA (18274)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (9)
Frontotemporal dementia (23)
Funding (1458)
Gene editing (200)
Generative AI (44)
Gene therapy (572)
GLP-1 (910)
Government (4705)
Grass and pollen (7)
Guidances (380)
Healthcare (18259)
HIV (56)
Huntington's disease (39)
IgA nephropathy (79)
Immunology and inflammation (223)
Immuno-oncology (53)
Indications (103)
Infectious disease (2939)
Inflammatory bowel disease (186)
Inflation Reduction Act (13)
Influenza (115)
Intellectual property (245)
Interviews (530)
IPO (14916)
IRA (45)
Job creations (3421)
Job search strategy (1947)
JPM (62)
Kidney cancer (17)
Labor market (75)
Layoffs (591)
Leadership (36)
Legal (6532)
Liver cancer (84)
Longevity (12)
Lung cancer (621)
Lymphoma (363)
Machine learning (40)
Management (54)
Manufacturing (743)
MASH (163)
Medical device (13037)
Medtech (13086)
Mergers & acquisitions (18743)
Metabolic disorders (1205)
Multiple sclerosis (150)
NASH (13)
Neurodegenerative disease (302)
Neuropsychiatric disorders (86)
Neuroscience (2785)
Neurotech (1)
NextGen: Class of 2026 (6383)
Non-profit (4350)
Now hiring (21)
Obesity (549)
Opinion (290)
Ovarian cancer (161)
Pain (200)
Pancreatic cancer (223)
Parkinson's disease (273)
Partnered (33)
Patents (495)
Patient recruitment (507)
Peanut (58)
People (61210)
Pharmaceutical (19)
Pharmacy benefit managers (26)
Phase 1 (20814)
Phase 2 (29117)
Phase 3 (21269)
Pipeline (5105)
Policy (271)
Postmarket research (2481)
Preclinical (8846)
Press Release (67)
Prostate cancer (241)
Psychedelics (41)
Radiopharmaceuticals (279)
Rare diseases (817)
Real estate (6035)
Recruiting (66)
Regulatory (22286)
Reports (40)
Research institute (2463)
Resumes & cover letters (408)
Rett syndrome (28)
RNA editing (15)
RSV (66)
Schizophrenia (144)
Series A (240)
Series B (184)
Service/supplier (8)
Sickle cell disease (93)
Special edition (15)
Spinal muscular atrophy (155)
Sponsored (43)
Startups (3379)
State (1)
Stomach cancer (11)
Supply chain (86)
Tariffs (67)
The Weekly (59)
Vaccines (970)
Venture capital (77)
Weight loss (337)
Women's health (81)
Worklife (21)
Date
Today (94)
Last 7 days (566)
Last 30 days (2004)
Last 365 days (28403)
2026 (3256)
2025 (28673)
2024 (32271)
2023 (36331)
2022 (46613)
2021 (51568)
2020 (50726)
2019 (44774)
2018 (34069)
2017 (30724)
2016 (30078)
2015 (35461)
2014 (28405)
2013 (24979)
2012 (26258)
2011 (26499)
2010 (24969)
Location
Africa (888)
Alabama (84)
Alaska (6)
Arizona (238)
Arkansas (14)
Asia (39917)
Australia (7070)
California (10325)
Canada (3050)
China (1053)
Colorado (438)
Connecticut (441)
Delaware (326)
Europe (91852)
Florida (1555)
Georgia (344)
Hawaii (3)
Idaho (59)
Illinois (868)
India (65)
Indiana (473)
Iowa (22)
Japan (410)
Kansas (118)
Kentucky (39)
Louisiana (26)
Maine (74)
Maryland (1271)
Massachusetts (7285)
Michigan (332)
Minnesota (561)
Mississippi (6)
Missouri (137)
Montana (34)
Nebraska (26)
Nevada (113)
New Hampshire (76)
New Jersey (2872)
New Mexico (30)
New York (2813)
North Carolina (1403)
North Dakota (10)
Northern California (4981)
Ohio (318)
Oklahoma (23)
Oregon (42)
Pennsylvania (2038)
Puerto Rico (24)
Rhode Island (45)
South America (1187)
South Carolina (52)
South Dakota (1)
Southern California (4102)
Tennessee (167)
Texas (1652)
United States (37053)
Utah (319)
Vermont (1)
Virginia (256)
Washington D.C. (66)
Washington State (853)
West Virginia (4)
Wisconsin (121)
Wyoming (2)
666,670 Results for "hebrew university of jerusalem".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson’s Disease
February 20, 2025
·
5 min read
Business
Adaptive Phage Therapeutics Enters Collaboration and License Agreement with Hebrew University of Jerusalem and Hadassah Medical Center
Adaptive Phage Therapeutics is pleased to announce a collaboration and license agreement with the Israeli Phage Therapy Center (IPTC) of the Hebrew University of Jerusalem and Hadassah Medical Center.
May 24, 2023
·
7 min read
Pharm Country
Beyond Air® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem
Beyond Air, Inc. announced that it has entered into an agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, LTD. to license the commercial rights for multiple neuronal nitric oxide synthase inhibitor candidates, currently being developed for the treatment of autism spectrum disorder and other neurological conditions.
June 15, 2023
·
12 min read
Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum
Clearmind Medicine Inc. announced the successful completion of two R&D projects with leading scientists from multiple disciplines at the Hebrew University as part of a collaboration established with the university’s technology transfer company, Yissum.
January 19, 2023
·
5 min read
Business
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem.
April 17, 2024
·
4 min read
Drug Development
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”) announced earlier this week successful results from a pre-clinical trial performed by Professor Joseph Tam from The Hebrew University of Jerusalem.
December 1, 2023
·
4 min read
Drug Development
Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial
Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”) announced positive results from its pre-clinical trial led by Professor Joseph Tam from The Hebrew University of Jerusalem, earlier this week.
December 1, 2023
·
6 min read
Press Releases
First-of-its-kind Universal Clearance Establishes Maximum Regulatory Access to the Bezier Parametric Curve Spinal Rod System for Patients and Surgeons
February 5, 2026
·
2 min read
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced successful results from a pre-clinical trial performed by Professor Joseph Tam from The Hebrew University of Jerusalem.
November 28, 2023
·
4 min read
Tarsier Pharma Announces Publication of Review Article on Suppressing Inflammation for Treating Retinal Blinding Ocular Diseases, Highlighting dazdotuftide (TRS) as a Promising Therapeutic Candidate
Tarsier Pharma Ltd. announced the publication of a review article authored by Dr. Vofo and Prof. Chowers, an AMD expert serving as the chairman of the Division of Ophthalmology at Hadassah Hebrew University Medical Center, Jerusalem, Israel .
June 12, 2023
·
3 min read
1 of 66,667
Next
